Boulding Mark Elliott 4

4 · PTC THERAPEUTICS, INC. · Filed Feb 19, 2026

AI-generated summary of this filing

Updated Feb 19, 2026

PTC Therapeutics (PTCT) EVP & CLO Mark Boulding Exercises Options, Sells

What Happened

Mark Elliott Boulding, Executive VP and Chief Legal Officer of PTC Therapeutics, exercised 2,813 option-derived shares on 2026-02-17 at $25.69 per share (exercise cost $72,266) and then sold the acquired shares and additional shares in open-market transactions on 2026-02-17 and 2026-02-18. Total reported sale proceeds were $408,612 across the trades. These actions are sales (routine monetization), not outright purchases.

Key Details

Transaction dates and amounts:
- 2026-02-17: Exercise (derivative conversion) 2,813 shares @ $25.69 — cost $72,266.
- 2026-02-17: Open-market sale 2,811 shares @ $69.29 — proceeds $194,774 (weighted avg; trades ranged $68.84–$69.80).
- 2026-02-17: Open-market sale 2 shares @ $70.13 — proceeds $140.
- 2026-02-18: Open-market sale 3,081 shares @ $69.36 — proceeds $213,698.
- Form also shows a $0 disposal entry for 2,813 derivative shares on 2026-02-17 (standard reporting when options are converted/exercised).
Total sale proceeds reported: $408,612; total exercise cost: $72,266.
Shares owned after the transactions: not specified in the provided filing excerpt.
Footnotes of note:
- F1: Some sales were effected under a written Rule 10b5-1 trading plan adopted Dec 4, 2024.
- F2: The $69.29 figure is a weighted average of multiple trades (range $68.84–$69.80).
- F3: A portion of shares were automatically sold to satisfy tax withholding tied to RSU vesting (sell-to-cover).
- F4: Options exercised were currently exercisable.
Filing was submitted Feb 19, 2026 for transactions reported on Feb 17–18, 2026 (no late-filing indication in provided data).

Context

This sequence reflects an option exercise followed by immediate or near-immediate open-market sales (a cashless exercise / sell-to-cover pattern). Some sales were executed under a pre-established 10b5-1 plan and some were automatic sell-to-cover actions to satisfy tax withholding on RSU vesting — both are routine mechanisms for insiders to meet tax obligations or diversify, and do not alone indicate management sentiment.

Form 4

Period: 2026-02-17

EXEC. VP AND CLO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-17$25.69/sh+2,813$72,266→ 114,125 total
Sale
Common Stock
[F1][F2]
2026-02-17$69.29/sh−2,811$194,774→ 111,314 total
Sale
Common Stock
[F1]
2026-02-17$70.13/sh−2$140→ 111,312 total
Sale
Common Stock
[F3]
2026-02-18$69.36/sh−3,081$213,698→ 108,231 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-02-17−2,813→ 22,501 total
Exercise: $25.69Exp: 2034-02-14→ Common Stock (2,813 underlying)

Footnotes (4)

[F1]This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.
[F2]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.84 to $69.80 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
[F3]Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a February 15, 2024 grant of 18,000 RSUs and the vesting of 1,600 RSUs from a February 15, 2024 grant of 3,200 RSUs.
[F4]Currently exercisable.

Signature

/s/ Avraham S. Adler, Attorney-in-Fact|2026-02-19

1 file